Shots:
- LYSA-LYSARC to conduct a P-II study to evaluate the safety and efficacy of valemetostat in six cohorts of patients with r/r B-cell lymphoma. The study will include ~140 patients at 22 sites in France and Belgium and is anticipated to be initiated in 2021
- The collaboration brings together Daiichi Sankyo’s science and the multidisciplinary expertise of the LYSA, LYSARC and the CALYM research consortium to conduct clinical and translational research that will build upon the ongoing P-I study of valemetostat in patients with r/r non-Hodgkin lymphoma
- Valemetostat (DS-3201) is an EZH1/2 dual inhibitor currently in clinical development for several hematologic cancers
Click here to read full press release/ article | Ref: Businesswire | Image: YouTube
The post Daiichi Sankyo Collaborates with LYSA-LYSARC-CALYM for Valemetostat in Patients with R/R B-Cell Lymphoma first appeared on PharmaShots.
